Cell and gene therapy has moved from academic curiosity to commercial reality. J&J’s Carvykti, BMS’s Breyanzi, Novartis’s Kymriah, and Gilead’s Yescarta collectively generate billions in annual revenues. Casgevy — the first CRISPR-based therapy — received approval for sickle cell disease and beta-thalassemia in late 2023, demonstrating that genome editing can deliver curative outcomes in a single administration. Manufacturing complexity, logistics, and pricing remain the primary barriers to broader commercial deployment.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• CAR-T Cell Therapy
• Gene Therapy In Vivo
• Gene Editing — CRISPR, Base Editing, Prime Editing
• TCR Therapy and TIL Therapy
• Manufacturing and Scale
• Regulatory Pathway
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. CAR-T Cell Therapy
4. Gene Therapy In Vivo
5. Gene Editing — CRISPR, Base Editing, Prime Editing
6. TCR Therapy and TIL Therapy
7. Manufacturing and Scale
8. Regulatory Pathway
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Technology Maturity Assessment 2025
Table 2. CAR-T Cell Therapy
Table 3. Gene Therapy In Vivo
Table 4. Gene Editing
Table 5. TCR Therapy and TIL Therapy
Table 6. Manufacturing and Scale
Table 7. Regulatory Pathway
Table 8. Leading Companies — Technology Investment and Strategy 2025
Table 9. M&A and Partnership Activity 2023-2025
Table 10. Key Risks and Mitigation Strategies
Companies Profiled
Spark Therapeutics
BioMarin
Sarepta
bluebird bio
Ultragenyx
Novartis Gene Therapies
Regenxbio
